Cost-Effectiveness of Exercise Therapy Versus Primary Stenting for Patients with Intermittent Claudication and Iliofemoral Disease  by Semel, Marcus E. et al.
JOURNAL OF VASCULAR SURGERY
854 Abstracts September 2013High-Dose-Rate Brachytherapy for the Treatment of In-Stent
Restenosis in the Lower Extremity
Karen J. Ho, Phillip M. Devlin, Arin L. Madenci, Marcus E. Semel, Louis L.
Nguyen, Michael Belkin, Edwin C. Gravereaux, Matthew T. Menard.
Brigham and Women’s Hospital, Boston, Mass
Objectives: The effectiveness of endovascular brachytherapy (EVBT)
for in-stent restenosis (ISR) after percutaneous transluminal angioplasty
(PTA) and stenting (PTAS) has been limited by edge stenosis and late
thrombosis. We evaluated a novel protocol of PTA and EVBT for ISR in
lower extremity occlusive disease.
Methods: We conducted a retrospective, single-center review of
patients treated with PTA and EVBT for ISR in the iliac and femoropopli-
teal segments between 11/2004 and 11/2012. Twenty Gy in a single frac-
tion was prescribed to 0.5 mm beyond the radius of the largest balloon and
with proximal and distal margins of at least 2 cm. Stents were duplexed at 1,
3, 6, 9, 12, and 18 months, and then yearly. The primary endpoint was
freedom from $75% restenosis in the treated segment. Patency data were
estimated using the Kaplan-Meier method.
Results: Forty-two consecutive cases of EVBT for ISR in iliac (24%;
n ¼ 10) and femoropopliteal (38%; n ¼ 32) arteries were performed.
Twenty patients (47.6%) had claudication, ﬁve (11.9%) had critical
limb ischemia, and 17 (40.4%) were asymptomatic. Median time from
stenting to EVBT was 594 days (interquartile range, 324-1124 days).
Thirteen (31%) patients underwent additional stent placement at time
of EVBT. Mean treated length was 23.5 6 12.3 cm over mean duration
of 16.1 6 9.6 minutes. Median post-EVBT follow-up time was 675 days
(interquartile range, 272-967 days). There were two periprocedural and
ﬁve late thrombotic occlusions. There was one death, thought to be
unrelated to EVBT. Post-EVBT patency data are shown in the Fig.
Primary-assisted patency rates for recurrent ISR of $50% were identical
to that of $75%.
Conclusions: EVBT appears to be a promising option for ISR in the
iliac and femoropopliteal arteries, particularly with a strategy of intervening
upon at-risk stents prior to occlusion. Future studies may help delineate
which patients will beneﬁt maximally from EVBT.Fig.Eph-B4 Activation Reduces Neointimal Hyperplasia in Human
Saphenous Vein
Daniel Wong, Kota Yamamoto, Clinton Protack, Daniel Lu, Michael Hall,
Roland Assi, Willis Williams, Nirvana Sadaghianloo, Hualong Bai, Alan
Dardik. Yale Medical School, New Haven, Conn
Introduction: Neointimal hyperplasia is the leading cause of vein
graft failure. Interventions aimed at inhibiting smooth muscle proliferation
have not succeeded in human studies. Eph-B4 induces venous identity, and
its expression is lost during venous adaptation. Previous studies have
demonstrated that exogenous stimulation of Eph-B4 with its ligand Eph-
rin-B2 reduces neointimal hyperplasia during murine vein graft adaptation.However, it is not known whether this pathway is active and can be manip-
ulated in human vein grafts. Thus our objective was to demonstrate that
activation of Eph-B4 with exogenous Ephrin-B2/Fc would reduce neointi-
mal hyperplasia in human saphenous veins in an in vitro model of neointimal
hyperplasia.
Methods: Excess saphenous vein was obtained from patients under-
going bypass surgery. Vein rings were cultured for 14 days with Ephrin-
B2/Fc at concentrations between 0 and 2 ug/mL. Each ring was
compared with its matched control for development of intimal hyperplasia
and quantitative real-time polymerase chain reaction was performed to
assess gene expression. Human umbilical vein endothelial cells were
treated with Ephrin-B2/Fc and receptor phosphorylation was detected
with western blot.
Results: Treatment of vein rings with Ephrin-B2/Fc led to an average
of 30.8% (95% conﬁdence interval, 6.56-55.0; n ¼ 20) decrease in neointi-
mal hyperplasia compared with controls. Eph-B4 and ephrin-B2 expression
signiﬁcantly decreased in organ culture while osteopontin expression
increased (n ¼ 7). Cultured endothelial cells demonstrated a signiﬁcant
increase in Eph-B4 phosphorylation when treated with Ephrin-B2/Fc as
well as increased phosphorylated of downstream signaling proteins AKT
and ERK.
Conclusions: The Eph-B4 signaling pathway is active in human
venous cells and stimulation of Eph-B4 in vitro leads to reduced neoimtimal
hyperplasia in saphenous vein rings. Stimulation of the Eph-B4 pathway may
be a promising candidate for a clinical trial to reduce vein graft neointimal
hyperplasia.
Cost-Effectiveness of Exercise Therapy Versus Primary Stenting for
Patients with Intermittent Claudication and Iliofemoral Disease
Marcus E. Semel, Karen J. Ho, C. Keith Ozaki, Michael Belkin. Brigham
and Women’s Hospital, Boston, Mass
Objectives: Supervised exercise (SE) is an evidence-based treatment
for intermittent claudication (IC). While primary stenting (PS) for iliofe-
moral occlusive disease may improve outcomes over angioplasty alone, it
may do so at increased cost. Although prior reports have failed to show
superiority of angioplasty over SE, we hypothesize that PS is cost-effec-
tive when compared with SE.
Table. Multivariate analysis of factors associated with 1-year AFS after
PVI (N ¼ 771)
Preoperative characteristic
Hazard
ratio
95% Conﬁdence
interval P value
Dialysis 2.9 2.0-4.2 <.01
Tissue loss 1.8 1.2-2.7 <.01
Dependent living status 1.8 1.1-2.9 .02
Male gender 1.6 1.2-2.1 .01
Congestive heart failure 1.5 1.2-2.0 <.01
Age >80 years 1.4 1.0-1.9 .049
Smoking (prior or current) 0.6 0.5-0.9 <.01
AFS, Amputation-free survival; PVI, peripheral vascular intervention.
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and ilio-femoral PS with a baseline strategy of nonsupervised exercise
(NSE). Estimates for costs and outcomes were obtained from the
medical literature (Table) and the Bureau of Labor Statistics. Costs
were adjusted to 2012 US Dollars. Effectiveness was measured as the
maximum walking distance (MWD) in meters by treadmill testing per-
formed at 1-year. The primary endpoint was cost-effectiveness measured
in dollars per meter walked. Because of a 1-year time horizon, discount-
ing was not used.
Results: The average cost-effectiveness of NSE/SE/PS in dollars per
meter walked was 15.4/19.8/51.6, respectively. When compared with
NSE, the incremental cost-effectiveness ratio for SE was $24.96/m. For
PS, it was $81.1/m. One-way sensitivity analyses (Table, Column 3)
demonstrated that SE was a robust strategy in that it was more cost-effective
than PS in all scenarios. PS was both more costly and less effective (ie, domi-
nated) if MWDPS <207 m or MWDSE >424 m.
Conclusion: When compared with NSE, SE is a more cost-effective
strategy than PS for the treatment of iliofemoral disease in IC.Determinants of Amputation-Free Survival After Peripheral Vascular
Intervention for Critical Limb Ischemia
Luke Vierthaler,1 Philip P. Goodney,2 Andres Schanzer,3 Virenda I. Patel,4
Jack L. Cronenwett,2 Daniel J. Bertges1, for the Vascular Study Group of
New England.1Univeristy of Vermont College Medicine, Burlington, Vt;
2Dartmouth Hitchcock Medical Center, Lebanon, NH; 3University of
Massachusetts Medical Center, Worchester, Mass; 4Massachusetts General
Hospital, Boston, Mass
Objectives: Our objective was to identify independent predictors
of overall (OS) and amputation-free survival (AFS) in patients under-
going peripheral vascular intervention (PVI) for critical limb ischemia
(CLI).
Methods: We reviewed 1253 patients who underwent 1414 PVI for
CLI within the Vascular Study Group of New England (VSGNE) from
January 2010 to December 2011. A univariate screen of potential predictors
of the primary (AFS) and secondary (OS) end points was performed to
construct a Cox proportional hazards model of survival at 1 year.
Results: All PVI were performed for CLI (rest pain 29%, tissue loss
71%). During each procedure, the number of arteries treated were one
(49%), two (35%), three (12%) and >four (5%). Target arterial segments
and TASC classiﬁcations were aorto-iliac (27%; A 49%, B 25%, C 11%, D
15%), femoral-popliteal (48%; A 30%, B 33%, C 20%, D 17%) and infrapopli-
teal (25%; A 17%, B 15%, C 27%, D 41%). Technical success was high (92%),
while complication rates were low (access site hematoma [5.0%] or occlusion
[0.3%], distal embolization [2.4%]). Mortality and major amputation rates
were 2.8% and 2.2% at 30 days, respectively. Overall percutaneous or open
reintervention rate was 8.0% at 1 year. The Kaplan-Meier estimates of 1-
year OS and AFS were 82% and 76%, respectively. Independent predictors
of AFS included male gender, age>80 years, dependent living status,congestive heart failure, dialysis dependence, and tissue loss; smoking was
protective (Table).
Conclusions: AFS after PVI for CLI is associated with speciﬁc preop-
erative patient characteristics. This data may facilitate efforts to improve
patient selection and, after further validation, enable risk-adjusted outcome
reporting for CLI patients undergoing PVI.Predictors of Increased Length of Stay Following Endovascular AAA
Repair
Virendra I. Patel, Shankha Mukhopadhyay, Mark F. Conrad, David C.
Brewster, Glenn M. LaMuraglia, Michael T. Watkins, Christopher J.
Kwolek, Richard P. Cambria. Massachusetts General Hospital, Boston, Mass
Objectives: Increased length of stay (LOS) following abdominal
aortic aneurysm (AAA) repair increases costs of care and serves as an impor-
tant quality metric. We sought to identify patient and procedural factors
associated with increased postoperative LOS following endovascular aneu-
rysm repair (EVAR).
Methods: All consecutive EVAR patients from a single institution (1/
2010-10/2012) were evaluated for increased LOS, deﬁned as >2 days.
Predictors of increased LOS were identiﬁed by univariate and multivariate
analysis.
Results: We identiﬁed 257 EVAR patients. Increased LOS was
observed in 63% of patients. Univariate analysis showed that patients with
increased LOS were older (78 6 10 vs 73 6 8 years; P < .01), female (27%
vs 14%; P¼ .01), smokers (88% vs 77%; P¼ .03), had coronary artery disease
(35% vs. 18%; P< .01), chronic obstructive pulmonary disease (36% vs 13%; P
< .01), prior AAA repair (11% vs 3%; P¼ .04), elevated creatinine>1.5 mg/
dL (16% vs 7%; P ¼ .05), and larger AAA (59 6 13 mm vs 54 6 8 mm;
P < .01). They were more likely to have general anesthesia (59% vs 44%;
P ¼ .03), longer operating room time (190 6 80 vs 130 6 40 minutes;
P < .01), receive more volume (1960 6 980 vs 1670 6 780 mL; P ¼ .02),
and have higher estimated blood loss (330 6 320 vs 190 6 140 mL; P <
.01). Patients staying >2 days were more likely to require vasopressors (11%
vs 3.4%; P ¼ .05), intensive care unit stay (20% vs 1%; P < .01), and return
to the operating room (5% vs 0%; P ¼ .03). Despite these differences, risk
adjusted independent predictors of increased LOS following EVAR included
symptomatic coronary artery disease (odds ratio [OR] 2.3; 95% conﬁdence
interval [CI], 1.2-4.7; P ¼ .01), chronic obstructive pulmonary disease (OR,
3.4; 95% CI, 1.4-7.9; P < .01), procedure time (per minute; OR, 1.02; 95%
CI, 1.01-1.03; P < .01), age (per year; OR, 1.04; 95% CI, 1.01-1.09; P ¼
.01), while preoperative statin use (OR, 0.29; 95% CI, 0.1-0.6; P < .01),
anddischarge to home (OR,0.07; 95%CI, 0.01-0.48;P< .01)was protective.
Chi-Pi analysis showed that both procedure time (33%) and disposition (26%)
combined accounted for more than half of the increased LOS.
Conclusions: These data highlight clinical and technical variables
associated with increased LOS following EVAR and may be utilized to enact
process improvement measures to improve patient care and reduce hospital
costs.Are Meta-Analyses and Systematic Reviews in Vascular Surgery
Reliable?
Felix J.V. Schlösser, Bauer E. Sumpio. Yale University, New Haven, Conn
Objectives: Meta-analyses (MAs) and systematic reviews (SRs) are
considered the highest level of evidence by the Oxford Centre for Evidence-
Based Medicine. The evidence-based minimum set of “Preferred Reporting
Items for Systematic Reviews andMeta-Analyses” (PRISMA) was introduced
in 2009. The objective of this protocol-driven study was to evaluate the
quality of MAs and SRs published in the Journal of Vascular Surgery.
